Literature DB >> 4591000

Treatment of acute herpes zoster with amantadine hydrochloride (Symmetrel).

A W Galbraith.   

Abstract

A double-blind, placebo-controlled trial of amantadine hydrochloride (Symmetrel) in acute herpes zoster (shingles) was carried out in 100 patients in general practice. The cases were serologically proved. There was no difference in duration of pain between the drug and placebo groups when pain disappeared during the 28 days' observation period. However, pain lasted more than 28 days in a significantly greater proportion of patients receiving placebo than of those on amantadine. Patients with pain after the 28-day observation period were significantly older than those whose pain disappeared during the study. The drug had no effect on rate of healing or appearance of new lesions.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4591000      PMCID: PMC1587865          DOI: 10.1136/bmj.4.5894.693

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study.

Authors:  A W Galbraith; J S Oxford; G C Schild; G I Watson
Journal:  Lancet       Date:  1969-11-15       Impact factor: 79.321

2.  Studies on induced influenza in man. I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain.

Authors:  Y Togo; R B Hornick; A T Dawkins
Journal:  JAMA       Date:  1968-03-25       Impact factor: 56.272

3.  The toxicologic and pharmacologic properties of amantadine hydrochloride.

Authors:  V G Vernier; J B Harmon; J M Stump; T E Lynes; J P Marvel; D H Smith
Journal:  Toxicol Appl Pharmacol       Date:  1969-11       Impact factor: 4.219

4.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

5.  Evaluation of amantadine hydrochloride in the treatment of A2 influenzal disease.

Authors:  R B Hornick; Y Togo; S Mahler; D Iezzoni
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

  5 in total
  9 in total

1.  Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the literature.

Authors:  K E Schmader; S Studenski
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

Review 3.  Treatment of shingles and post-herpetic neuralgia.

Authors:  J V Jolleys
Journal:  BMJ       Date:  1989-06-10

4.  Postherpetic neuralgia.

Authors:  P N Robinson; N Fletcher
Journal:  J R Coll Gen Pract       Date:  1986-01

Review 5.  Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials.

Authors:  T Lancaster; C Silagy; S Gray
Journal:  Br J Gen Pract       Date:  1995-01       Impact factor: 5.386

6.  Topical acyclovir in herpes zoster ocular involvement.

Authors:  J McGill
Journal:  Br J Ophthalmol       Date:  1981-08       Impact factor: 4.638

Review 7.  Herpes zoster and postherpetic neuralgia. Optimal treatment.

Authors:  R W Johnson
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 8.  Treatment of postherpetic neuralgia: an update.

Authors:  G E Kanazi; R W Johnson; R H Dworkin
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 9.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.